# Silence Therapeutics surges 25% premarket after announcing positive topline results from phase 1 multiple dose study of Zerlasiran
**FDA Update**

**2023-11-01 12:11**

**https://www.ainvest.com/news/silence-therapeutics-surges-25-premarket-after-announcing-positive-topline-results-from-phase-1-multiple-dose-study-of-zerlasiran-23111000de0998e827fc2918/**

Silence Therapeutics surges 25% premarket after announcing positive topline results from phase 1 multiple dose study of Zerlasiran